feeling weak on semaglutide Ozempic (semaglutide) is a GLP-1 receptor agonist used for type 2 diabetes (and sometimes weight loss). Its side effects range from common GI symptoms to rare but serious risks. ⸻ 🟡 Common Ozempic (semaglutide) is commonly used

Patients who experience nausea, vomiting, or diarrhea that leads to dehydration may be at higher risk for kidney issues

Plasma donation takes about 90 minutes to two hours for the entire process, with the actual donation time about 30-45 minutes

Our results demonstrated that of the 109 patients with CC, 72 (66.1%

The GLP-1 receptor/GIP receptor/GCGR triple agonist efocipegtrutide is presently under investigation in individuals with MASLD, and preclinical accounts of other dual and triple agonists that include GLP-1 receptor and GCGR agonism suggest that clinical studies in individuals with type 2 diabetes will follow [62, 63]

Clinical diabetes: a publication of the American Diabetes Association, 42(1), 7486

In some cases, temporary dose reduction, medication substitution, or additional supportive care may resolve compatibility concerns while maintaining both infection treatment and weight loss momentum